Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides long‑term contraception for up to five years and prevents pregnancy in women of reproductive age.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert, a hormonal intrauterine contraceptive, is indicated for the following clinical uses:

Long‑term contraception: Provides up to five years of reliable birth control for women of reproductive age. Prevention of pregnancy: Acts as a primary method to prevent fertilisation and implantation.

Levosert may cause a range of adverse reactions. Monitoring and reporting are recommended.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal discomfort after insertion - Breast tenderness or enlargement - Mood changes or headache - Vaginal discharge

Serious or Rare Side Effects: - Uterine perforation during insertion - Device expulsion or displacement - Pelvic inflammatory infection - Ectopic pregnancy if contraceptive failure occurs - Severe allergic reaction to device components

Before insertion of Levosert, certain precautions should be observed.

Screen for pregnancy: Confirm the patient is not pregnant prior to insertion. Assess uterine anatomy: Evaluate for fibroids, septa, or other anomalies that may affect placement. Monitor for infection: Observe for signs of pelvic infection after the procedure. Avoid use in active pelvic infection: Do not insert in the presence of untreated sexually transmitted infections. Contraindicated in known or suspected pregnancy: The device must not be placed in pregnant women. Store at room temperature: Keep in the original packaging, protect from moisture and direct sunlight, and store below 25 °C.

Levosert may interact with other medications that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): May reduce contraceptive efficacy. - Rifampicin or other strong CYP3A4 inducers: Can lower levonorgestrel levels. - Certain antiretroviral protease inhibitors: May increase hormone concentrations leading to side effects.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline: May slightly affect hormone levels, though clinical impact is minimal. - Herbal supplements containing St. John’s wort: Potential to reduce contraceptive effectiveness.